By Fineline Cube 
China-based 4B Technologies Investments Ltd has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its first-in-class (FIC) Category 1 drug 4B02-01, targeting amyotrophic lateral sclerosis (ALS).
ALS and 4B02-01 Mechanism
ALS is a life-threatening degenerative motor neuron disease. Patients suffer from damage to upper and lower motor neurons, leading to a sustained decline in motor function, muscle atrophy, weakness, and ultimately respiratory failure and death. 4B02-01 works through a TrkB receptor agonism mechanism and shows synergistic potential with two other pipeline candidates: the CSF1R inhibitor 4B71-01, which targets neuroinflammatory pathways, and the AI-optimized compound 4B06-01, which modulates neuronal signal transduction.
Triple Therapeutic Strategy
This triple-therapeutic strategy aims to address the multifaceted pathophysiology of ALS by targeting complementary biological pathways. The approach highlights 4B Technologies’ commitment to developing innovative treatments for this devastating condition.-Fineline Info & Tech